Corpay vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 79)

Corpay

LeaderConsumer Finance

Enterprise

Atlanta B2B payments (NYSE: CPAY, rebranded from FLEETCOR) at $3.975B FY2024 revenue; fleet cards, AP automation, Cambridge cross-border payments, Q4 organic growth +12%, adjusted net income $1.4B competing with WEX.

AI VisibilityBeta
Overall Score
B79
Category Rank
#200 of 290
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
82
Gemini
78

About

Corpay, Inc. is an Atlanta, Georgia-based B2B payments technology company — publicly traded on the New York Stock Exchange (NYSE: CPAY) as an S&P 500 Financials component (rebranded from FLEETCOR Technologies to Corpay in 2024) — providing corporate fleet card payments, virtual card accounts payable automation, cross-border currency payments, and lodging payment management to corporate, government, and commercial vehicle fleet customers in 100+ countries through approximately 10,000 employees. In fiscal year 2024, Corpay reported record Q4 revenues of $1.034 billion (+10% year-over-year) with organic revenue growth of 12% and adjusted EPS growth of 21%, and full-year revenues of $3.975 billion with adjusted net income of $1.4 billion. The company is organized across three segments: Vehicle Payments (fleet fuel cards, tolling solutions, and vehicle-related expense management — the original FLEETCOR fleet card business), Corporate Payments (virtual cards, AP automation, and cross-border B2B payments through the Cambridge Global Payments platform), and Lodging Payments (corporate lodging payment solutions for trucking, construction, and hospitality workforce programs). CEO Ron Clarke has led Corpay's growth through a decade of acquisitions, rebranding the company as Corpay in 2024 to reflect the expanding portfolio beyond fleet cards into the broader B2B payments market.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

79
Overall Score
90
#200
Category Rank
#9
70
AI Consensus
60
stable
Trend
stable
78
ChatGPT
99
82
Perplexity
99
78
Gemini
83
84
Claude
96
90
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.